New drug combo tested in kids with Tough-to-Treat leukemia

NCT ID NCT05292664

Summary

This early-stage study aims to find the safest and most effective dose of a drug called venetoclax when given alongside standard chemotherapy. It is for children, teens, and young adults up to age 40 with high-risk blood cancers like leukemia and myelodysplastic syndrome (MDS) that have come back or not responded to prior treatment. The main goal is to see how well the combination is tolerated and to measure its effects on the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ann & Robert H Lurie Children's Hospital of Chicago

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Healthcare of Atlanta at Arthur M. Blank Hospital

    RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Hospital Colorado

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of California San Francisco-Benioff Children's Hospital

    RECRUITING

    San Francisco, California, 94158, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.